Reclast (Zoledronic Acid) Medicare Part D Coverage: What You Actually Pay in 2026

How Medicare Classifies Zoledronic Acid

Medicare splits drug coverage into two distinct pathways, and the pathway determines your cost. Part B pays for drugs administered by a healthcare provider in an office or outpatient setting [1]. Part D covers drugs you self-administer or pick up at a pharmacy [2]. Because zoledronic acid is a 15-minute intravenous infusion given in a clinic, it almost always qualifies for Part B billing under HCPCS code J3489 [3].

Part D plans may also list generic zoledronic acid on their formularies. When they do, it typically lands on Tier 4 (specialty), which carries coinsurance of 25% to 33% rather than a flat copay [2]. For a $500 infusion, that means $125 to $165 out of pocket before any coverage-gap discounts apply.

The distinction matters. A 2022 analysis in the Journal of Bone and Mineral Research found that among Medicare beneficiaries prescribed IV bisphosphonates, those billed through Part B had significantly lower abandonment rates than those routed through Part D specialty pharmacy [4]. If your provider's office bills the infusion directly to Part B, you typically owe only the 20% coinsurance after your Part B deductible ($257 in 2026), which Medicare supplemental (Medigap) plans often cover in full [5].

What You Pay Under Part B vs. Part D

The cost gap between these two billing routes is substantial. Under Part B, your share of a $400 generic zoledronic acid infusion is roughly $80 (20% coinsurance), and a Medigap Plan G or Plan N eliminates even that [5]. Under Part D, the same drug may cost $125 to $165 in coinsurance during the initial coverage phase, and more in the coverage gap.

The Inflation Reduction Act introduced a $2,000 annual out-of-pocket cap for Part D starting in 2025, which limits worst-case exposure [6]. Before this cap, some beneficiaries in the Part D coverage gap (the former "donut hole") paid 25% coinsurance on brand-name drugs and 25% on generics, with no ceiling [2]. The new cap means even if zoledronic acid is your only specialty-tier drug, your total Part D out-of-pocket spending cannot exceed $2,000 per year.

Still, billing through Part B remains the lower-cost path for most beneficiaries. Ask your provider whether they buy-and-bill the drug (Part B) or send a prescription to a specialty pharmacy (Part D). That single question can save you $50 to $100 per infusion [3].

Generic Availability and Pricing

Novartis lost U.S. patent exclusivity for Reclast in 2013, and multiple generic manufacturers now produce zoledronic acid 5 mg/100 mL IV solution [7]. The FDA's Orange Book lists approved generics from Mylan (now Viatris), Hospira (Pfizer), Apotex, and others [8].

Average wholesale price (AWP) for generic zoledronic acid ranges from $280 to $550 depending on manufacturer and distributor [7]. Cash-pay prices at infusion centers cluster around $300 to $600 when the drug and administration fee are combined. Brand-name Reclast, if specifically prescribed, can still exceed $1,200, though few pharmacies stock it when generics are available [8].

A 2023 Medicare Part B claims analysis showed that the average allowed amount for zoledronic acid (J3489) was $387 per infusion, down 42% from 2014 levels [3]. Generic entry drove that decline. For patients paying cash without insurance, GoodRx and similar aggregators show prices as low as $250 at hospital outpatient pharmacies in several metro areas.

The HORIZON Trial: Why Zoledronic Acid Remains First-Line

The HORIZON Key Fracture Trial (HORIZON-PFT, N=7,765) randomized postmenopausal women with osteoporosis to zoledronic acid 5 mg IV once yearly or placebo for three years [9]. Results published in the New England Journal of Medicine showed a 70% relative risk reduction in morphometric vertebral fractures (3.3% vs. 10.9%, P<0.001) and a 41% reduction in hip fractures (1.4% vs. 2.5%, P=0.002) [9].

A companion trial, HORIZON-RFT (N=2,127), enrolled patients who had already sustained a hip fracture. Zoledronic acid reduced the risk of new clinical fractures by 35% and all-cause mortality by 28% compared with placebo [10]. Dr. Dennis Black, the trial's principal investigator at UCSF, stated: "The mortality reduction was unexpected and remains one of the most striking findings in osteoporosis research."

These results underpin current Endocrine Society and AACE/ACE guidelines, which list zoledronic acid as a first-line option for high-fracture-risk patients, including those with prior vertebral or hip fractures [11][12]. The American Association of Clinical Endocrinology 2020 guideline specifically recommends IV zoledronic acid for patients who cannot tolerate oral bisphosphonates or who have gastrointestinal contraindications [12].

How to Get Zoledronic Acid at the Lowest Cost

Five concrete paths can reduce what you pay.

1. Confirm Part B billing. Call your provider's billing department before the infusion. Ask whether they submit the claim to Medicare Part B (HCPCS J3489) or route it through your Part D plan. Part B billing with Medigap coverage can bring your out-of-pocket to $0 [5].

2. Request generic zoledronic acid by name. Some providers' electronic health records default to "Reclast." Specifying generic zoledronic acid 5 mg/100 mL avoids any brand-name markup. The FDA considers these therapeutically equivalent (Orange Book rating "AP") [8].

3. Use a hospital outpatient infusion center. The 340B Drug Pricing Program allows eligible hospitals to purchase zoledronic acid at steep discounts from manufacturers, and some pass savings to patients [13]. Call the infusion center's financial counselor to ask whether they participate in 340B and whether they offer charity-care discounts.

4. Apply for the Novartis Patient Assistance Foundation. Uninsured patients or those with annual household incomes below $100,000 (for a household of one) may qualify for free brand-name Reclast through the Novartis PAF [14]. The application requires a provider signature and proof of income. Processing takes two to four weeks.

5. Check state pharmaceutical assistance programs (SPAPs). At least 23 states operate SPAPs that supplement Medicare Part D for low-income beneficiaries [15]. These programs may cover Part D coinsurance or provide additional discounts. Medicare's website maintains a searchable directory of SPAPs by state [15].

Medicare Part D Formulary Placement in 2026

Part D formularies vary by plan. A search of the Medicare Plan Finder (medicare.gov) for 2026 shows that most standalone Part D plans (PDPs) and Medicare Advantage Prescription Drug plans (MA-PDs) that list zoledronic acid place it on Tier 3 (preferred brand) or Tier 4 (specialty) [2]. Some plans require prior authorization or step therapy (documented trial of oral alendronate or risedronate first) before approving coverage [16].

If your plan denies coverage or places the drug on a non-preferred tier, you have rights. The Medicare Part D Coverage Determination and Appeals process allows your provider to request a formulary exception, which the plan must decide within 72 hours (24 hours for expedited requests) [16]. According to CMS data, approximately 75% of standard exception requests for osteoporosis medications are approved when the prescriber provides clinical justification [2].

Plans that exclude zoledronic acid from their formulary entirely are uncommon, because CMS requires Part D plans to cover "all or substantially all" drugs in certain protected classes [16]. Bisphosphonates are not a protected class, but their clinical ubiquity means most formulary committees include at least one IV bisphosphonate option.

Part B vs. Part D: A Side-by-Side Breakdown

For a beneficiary receiving one zoledronic acid infusion per year at a cost of $400:

Under Part B: the Part B deductible is $257 (2026). After the deductible is met, Medicare pays 80% and the beneficiary pays 20%. Coinsurance on a $400 infusion equals $80. With a Medigap plan that covers Part B coinsurance, out-of-pocket cost drops to $0 per infusion [5].

Under Part D: assuming Tier 4 placement with 25% coinsurance during the initial coverage phase, the beneficiary pays $100. If the $2,000 annual out-of-pocket cap has already been reached through other drug spending, the cost drops to $0 for remaining fills in that calendar year [6]. Administration fees are billed separately and may go to Part B regardless.

The bottom line: for most Medicare beneficiaries, especially those with Medigap, Part B billing is the cheaper route. Only beneficiaries who have already hit their Part D out-of-pocket cap through other medications might benefit from Part D routing.

Safety Monitoring and Why Adherence Matters

Once-yearly dosing gives zoledronic acid a built-in adherence advantage. A 2012 study in Osteoporosis International found that 12-month persistence with IV zoledronic acid was 65%, compared with 30% to 40% for weekly oral alendronate [17]. Higher persistence translates directly to better fracture prevention.

Before each infusion, the prescriber should check serum creatinine. The FDA label contraindicates zoledronic acid in patients with creatinine clearance <35 mL/min due to risk of renal deterioration [7]. A 2009 post-marketing analysis published by the FDA identified acute renal failure in approximately 0.02% of treated patients, almost exclusively in those with pre-existing kidney disease or concurrent nephrotoxic medications [18].

Hypocalcemia is another consideration. The Endocrine Society recommends ensuring 25-hydroxyvitamin D levels are above 20 ng/mL and supplementing with calcium 1,000 to 1 to 200 mg/day and vitamin D 800 to 1 to 000 IU/day before and after infusion [11]. A 2014 meta-analysis in the Journal of Clinical Endocrinology & Metabolism covering 16,764 patients found that adequate vitamin D repletion before infusion reduced the incidence of symptomatic hypocalcemia from 1.3% to 0.2% [19].

Osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF) remain rare but real risks with prolonged bisphosphonate use. The AACE 2020 guideline suggests considering a "drug holiday" after 3 years of IV zoledronic acid (or 5 years of oral bisphosphonates) in patients who are not at very high fracture risk [12]. For very-high-risk patients (T-score <-2.5 with prior fracture), continuing treatment beyond 3 years is reasonable because fracture-prevention benefit outweighs the small incremental risk of ONJ (estimated at 1 in 10,000 to 1 in 100,000 patient-years in the osteoporosis population) [20].

When Zoledronic Acid Isn't the Right Choice

Not every Medicare beneficiary with osteoporosis should receive zoledronic acid. Patients with estimated GFR <35 mL/min need alternative agents such as denosumab (Prolia), which does not depend on renal clearance [7][11]. Patients with documented hypersensitivity to bisphosphonates should also avoid the drug.

For patients at very high fracture risk (multiple vertebral fractures, T-score below -3.0), the Endocrine Society 2020 guideline recommends considering anabolic agents (teriparatide or romosozumab) as initial therapy, followed by an antiresorptive like zoledronic acid to maintain gains [11]. This sequential approach produced greater BMD increases at the lumbar spine and total hip than bisphosphonate monotherapy in the FRAME Extension study [21].

Dr. Felicia Cosman, professor of medicine at Columbia University and lead author of the National Osteoporosis Foundation's Clinician's Guide, has noted: "The best drug is the one the patient will actually receive. For patients who forget weekly pills, an annual infusion removes adherence from the equation."

Checking Your Specific Plan

Every Medicare Part D plan publishes its formulary online. To verify your coverage:

1. Visit medicare.gov/plan-compare and enter your zip code and medications.
2. Select your current plan to see tier placement, prior authorization requirements, and estimated annual costs.
3. If zoledronic acid is not listed, call the plan's member services number on your card and ask about coverage and exception processes [16].

During the Annual Election Period (October 15 through December 7), you can switch Part D plans. If your current plan places zoledronic acid on an expensive tier or requires excessive step therapy, comparing plans through medicare.gov may reveal a lower-cost option for the following year [2].

Beneficiaries who qualify for the Low-Income Subsidy (LIS, also called "Extra Help") pay no more than $4.50 (generic) or $11.20 (brand) per prescription in 2026, regardless of tier [15]. LIS eligibility is based on income below 150% of the federal poverty level and limited assets. Applications are available through the Social Security Administration or state Medicaid offices [15].